Literature DB >> 15520174

Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway.

Debdutta Bandyopadhyay1, Anupam Mishra, Estela E Medrano.   

Abstract

Melanoma cells typically express wild-type p53, yet they are notoriously resistant to DNA-damaging agents. Here, we show that sodium butyrate (NaB), a histone deacetylase (HDAC) inhibitor, induced apoptosis in human melanoma cells in a dose- and time-dependent manner. Apoptosis was associated with HDAC1-dependent induction of Bax and acetylation of p53. Down-regulation of HDAC1 by an antisense vector sensitized the cells to NaB-induced apoptosis, whereas its overexpression conferred resistance to this agent. Increased HDAC1 levels and activity impaired NaB-mediated activation of Bax promoter and Bax protein levels. Finally, using p53-null melanoma cell line and RNA interference in cells expressing wild-type p53 protein, we show that Bax induction and NaB-mediated apoptosis is p53 dependent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520174     DOI: 10.1158/0008-5472.CAN-03-3897

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Inhibition of mouse B16 melanoma by sodium butyrate correlated to tumor associated macrophages differentiation suppression.

Authors:  Fen Xiong; Yun-Zhu Mou; Xiao-Yan Xiang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Histone acetylation and reactive oxygen species are involved in the preprophase arrest induced by sodium butyrate in maize roots.

Authors:  Qi Zhang; Pu Wang; Haoli Hou; Hao Zhang; Junjun Tan; Yan Huang; Yingnan Li; Jinping Wu; Zhengming Qiu; Lijia Li
Journal:  Protoplasma       Date:  2016-01-19       Impact factor: 3.356

3.  Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies.

Authors:  Luca Sigalotti; Alessia Covre; Elisabetta Fratta; Giulia Parisi; Francesca Colizzi; Aurora Rizzo; Riccardo Danielli; Hugues J M Nicolay; Sandra Coral; Michele Maio
Journal:  J Transl Med       Date:  2010-06-11       Impact factor: 5.531

Review 4.  Targeting tumour-supportive cellular machineries in anticancer drug development.

Authors:  Matthias Dobbelstein; Ute Moll
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

5.  HDAC1 cooperates with C/EBPalpha in the inhibition of liver proliferation in old mice.

Authors:  Guo-Li Wang; Elizabeth Salisbury; Xiurong Shi; Lubov Timchenko; Estela E Medrano; Nikolai A Timchenko
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

6.  HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta.

Authors:  Guo-Li Wang; Elizabeth Salisbury; Xiurong Shi; Lubov Timchenko; Estela E Medrano; Nikolai A Timchenko
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

7.  Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis.

Authors:  Fumihiko Hayakawa; Akihiro Abe; Issay Kitabayashi; Pier Paolo Pandolfi; Tomoki Naoe
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

Review 8.  Recent advances in histone deacetylase targeted cancer therapy.

Authors:  Isamu Hoshino; Hisahiro Matsubara
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

Review 9.  Role of HDAC1 in senescence, aging, and cancer.

Authors:  Danielle Willis-Martinez; Hunter W Richards; Nikolai A Timchenko; Estela E Medrano
Journal:  Exp Gerontol       Date:  2009-10-08       Impact factor: 4.032

10.  Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction.

Authors:  Andrew J Wilson; Anderly C Chueh; Lars Tögel; Georgia A Corner; Naseem Ahmed; Sanjay Goel; Do-Sun Byun; Shannon Nasser; Michele A Houston; Minaxi Jhawer; Helena J M Smartt; Lucas B Murray; Courtney Nicholas; Barbara G Heerdt; Diego Arango; Leonard H Augenlicht; John M Mariadason
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.